Goodbye to PCOS: the new term that will change how we understand it

1. The historical error of the term SOP

Polycystic ovary syndrome (PCOS) is a very common condition seen in gynecology and assisted reproduction clinics, affecting one in eight women. However, the scientific community has recognized that the term PCOS is inaccurate, as it misleadingly suggests the presence of pathological ovarian cysts.

In reality, what is observed in the ovaries are not true pathological cysts, but follicles whose development has stopped. The use of an incorrect term has had serious consequences:

• It hides the various endocrine and metabolic characteristics of the patient.
• Contribute to retrasos significant in the diagnosis, leaving up to 70% of affected people without a clear diagnosis.

Furthermore, it fosters stigmatization and fragmentation in medical care.

2. PMOS: The new key diagnostic tool

In response to this need for evolution, an unprecedented global consensus process has emerged. As a result, the condition formerly known as polycystic ovary syndrome now has a new name: polyendocrine metabolic ovarian syndrome , known by its acronym PMOS . This new name was carefully chosen because it accurately reflects the multisystemic pathophysiology of the condition.

By omitting the word cysts, the widespread confusion is eliminated and the true essence of the condition is captured: a combined endocrine, metabolic, and ovarian dysfunction.

3. Real impact of PMOS on health

To understand the importance of PMOS, it is necessary to understand that its characteristics go far beyond a simple ovarian or gynecological problem. Science and international guidelines have demonstrated that this condition is based on endocrine alterations related to insulin, androgens, and ovarian hormones. The syndrome encompasses multiple body systems:

• Traits reproductive: ovulatory disorders, irregular menstrual cycles, difficulty achieving pregnancy, gestational complications, and endometrial cancer.
• Traits metabolic: greater predisposition to glucose disorders, hypertension, dyslipidemia and even sleep apnea.
• Traits dermatological: acne, alopecia, or hair growth in areas that are not common in women.

In addition, it also has psychological traits, such as depression, anxiety, low quality of life, and eating disorders.

4. The future of patients with PMOS

The path toward the full adoption of the name polyendocrine metabolic ovarian syndrome (PMOS) is already underway. A global implementation strategy has been designed that includes a structured three-year transition and refinement period.

This scientific evolution will allow for greater awareness, improved diagnosis and quality of medical care, eliminating the anxiety caused by an outdated name and providing a truly comprehensive approach to women suffering from this syndrome.

5. Community and Support

At Assisted Reproduction ORG, we strive to make accurate and reliable monthly information accessible to everyone. If this article has helped you, please consider supporting us so we can continue to help more people on their journey to parenthood.